8-K: Grace Therapeutics Announces Fiscal Q2 2025 Results, STRIVE-ON Trial Data Expected in Early 2025

Grace Therapeutics reported its fiscal second quarter 2025 financial results, highlighted by the completion of patient enrollment in the Phase 3 STRIVE-ON trial and a projected cash runway into the second quarter of 2026.

Summary

• Grace Therapeutics announced its financial results for the fiscal quarter ended September 30, 2024.
• The company reported a net loss of $3.4 million, or $0.30 per share, which is a slight increase from the $3.3 million loss, or $0.43 per share, in the same quarter of the previous year.
• The increased loss was primarily due to a $2.5 million rise in research and development expenses related to the GTx-104 clinical trial.
• General and administrative expenses also increased by $0.3 million to $1.9 million.
• The company's cash and cash equivalents decreased by $7.9 million to $15.1 million as of September 30, 2024.
• Grace Therapeutics anticipates a data readout from the STRIVE-ON trial in the first calendar quarter of 2025 and plans to submit a New Drug Application (NDA) in the first half of 2025.
• The company has completed its corporate re-branding and redomiciled to Delaware.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the completion of patient enrollment, the anticipated NDA submission, and the projected cash runway. However, the increased net loss and decrease in cash are areas of concern.

Positives

• The company completed patient enrollment in the Phase 3 STRIVE-ON trial ahead of schedule.
• The company is on track to submit an NDA to the FDA in the first half of 2025.
• The company has successfully rebranded and redomiciled to Delaware.
• The company has a projected cash runway into the second calendar quarter of 2026.
• GTx-104 has been administered in over 150 healthy volunteers and was well tolerated with significantly lower interand intra-subject pharmacokinetic variability compared to oral nimodipine.

Negatives

• The company reported a net loss of $3.4 million for the quarter, an increase from the previous year.
• Cash and cash equivalents decreased by $7.9 million during the quarter.
• Research and development expenses increased significantly due to the GTx-104 trial.

Risks

• The success and timing of regulatory submissions for GTx-104 are uncertain.
• Regulatory requirements and the outcome of the NDA application are subject to change.
• Clinical trial designs and regulatory pathways could be altered.
• Legislative, regulatory, political, and economic developments could impact the company.
• Actual costs associated with clinical trials may differ from management's expectations.

Future Outlook

The company anticipates a data readout from the STRIVE-ON trial in the first calendar quarter of 2025 and plans to submit a New Drug Application (NDA) to the FDA in the first half of 2025. The company believes its existing cash will fund operations into the second calendar quarter of 2026.

Management Comments

• Prashant Kohli, CEO of Grace Therapeutics, stated that the company made significant progress in both clinical and corporate goals during the second quarter.
• Mr. Kohli also mentioned that the rebranding to Grace Therapeutics reconnects the company to its rich scientific legacy.
• Mr. Kohli believes the redomicile to the United States offers potential benefits, including increased attractiveness to strategic partners and global institutional investors.

Industry Context

This announcement is relevant to the biopharmaceutical industry, particularly companies focused on developing treatments for rare and orphan diseases. The progress of GTx-104 is of interest to those following advancements in treatments for aneurysmal subarachnoid hemorrhage (aSAH). The company's focus on novel drug delivery technologies aligns with a broader trend in the industry to improve drug performance and patient convenience.

Comparison to Industry Standards

• The increase in R&D spending is typical for a company in late-stage clinical trials, such as Grace Therapeutics, as they invest heavily in pivotal studies like the STRIVE-ON trial. Companies like Neurocrine Biosciences and Biohaven Pharmaceuticals have also seen significant R&D increases during late-stage development.
• The reported net loss is not unusual for a pre-revenue biopharmaceutical company, as these companies typically operate at a loss until they achieve commercialization. Companies like Alnylam Pharmaceuticals and Sarepta Therapeutics have also reported losses during their development phases.
• The cash runway projection into the second quarter of 2026 is a positive sign, indicating the company has sufficient funding for its near-term goals. This is comparable to other companies in the sector that have secured funding to support their clinical programs, such as Argenx and Global Blood Therapeutics.
• The completion of patient enrollment ahead of schedule is a positive indicator of efficient trial management, which is a key factor in the success of clinical programs. This is similar to companies like Vertex Pharmaceuticals that have demonstrated efficient trial execution.

Corporate Governance

Stakeholder Impact

• Shareholders will be interested in the progress of the STRIVE-ON trial and the NDA submission.
• Employees may be impacted by the company's financial performance and strategic decisions.
• Patients with aSAH stand to benefit from the potential approval of GTx-104.
• Potential strategic partners and investors will be evaluating the company's progress and financial stability.

Next Steps

• The company will proceed with data analysis from the STRIVE-ON trial.
• The company will prepare and submit a New Drug Application (NDA) to the FDA.
• The company will host a virtual KOL event on GTx-104 on November 20, 2024.

Key Dates

Keywords

Grace Therapeutics, GTx-104, STRIVE-ON trial, NDA submission, Aneurysmal Subarachnoid Hemorrhage, aSAH, Nimodipine, Clinical Trial, Biopharma, Orphan Drug Designation